从投资者的视角下,主要研究R&D投入对投资者反应的影响,以及企业财务状况对R&D投入价值评价所起到的信号作用。基于市场信号理论和战略匹配理论,R&D投入被看作是一个具有不确定可信度与质量的信号.作为R&D投入匹配能力的财务状况向投资者发出了有关R&D信号可信度与质量的重要信息,并进一步影响了R&D投入与投资者反应之间的关系。采用2007-2011年医药行业上市公司的数据进行回归分析,研究结果表明:(1)R&D投入是一个积极的正向信号,投资者对该信号产生了显著的正向回应;(2)高发展能力提高了R&D信号的可信度,使得R&D投入与投资者反应之间形成了更强的正向关系;(3)高负债水平降低了R&D信号的可信度,使得R&D投入与投资者反应之间的正向关系变弱;(4)盈利能力并没有影响投资者对R&D信号可信度的判断,因此不存在信号作用。
From the perspective of investors, this paper examines the impact of R&D on investors' reaction and the signaling role of financial statement in evaluating the value of R&D investment. Building on signaling theory and strategic fit theory, R&D investment is regarded as a signal with uncertainty credibility and quality, this paper propose that financial statements of firms send important signals to the investment community regarding the credibility of R&D investments, which in turn impact the stock market reaction to R&D investment. Using data of the listed pharmaceutical firms from 2007 to 2011, this paper finds that: ( 1 ) R&D investment is a positive signal, investors has a significant positive reaction to this signal ; ( 2 ) a high growth rate will improve the credibility of R&D signal, leading to a stronger positive relationship between R&D and investors' reaction; (3) a high debt asset ratio will reduce the credibility of R&D signal, leading to a weaker positive relationship between R&D investment and investors' reaction; (4) This is no evidence that profitability has a signaling role between R&D investment and investors' reaction.